BNET Industries

Large Scale Biology Corp.

is in the Pharma Industry

Last Fiscal Year Sales:$1.7M
  • Private
  • US
Dow Jones Description

Large Scale Biology Corporation's (LSBC) goal is to develop, manufacture and commercialize plant-made pharmaceutical proteins and vaccines. LSBC has successfully garnered an international reputation as an innovator in biomanufacturing. Driven by its unique GENEWARE RNA plant viral gene expression technology, LSBC has taken integration of plant-made pharmaceuticals from gene to production further than any other company. GENEWARE technology is complemented by a full commercial-scale capability to produce, extract, purify, finish and fill a wide range of pharmaceutical proteins. LSBC's proprietary core technologies radically extend the power of product development, improvement and manufacture. LSBC is pursuing an aggressive, market-oriented business model designed to take full advantage of its technological lead and its ability to integrate all major components in the product pipeline. LSBC's technologies and discoveries are protected by an extensive portfolio of foreign and domestic patents, and the company has formed several major alliances and partnerships to maximize its market opportunities. LSBC's ability to bring innovative tools to the forefront of the life sciences industry is well documented, and the company can proudly claim a number of industry firsts, including: the first practical plant-virus-based manufacturing platform, the first release of a safe, transgenic virus into a controlled outdoor environment under government permit, the world's first cancer vaccine...

Vice President and Executive Program ManagerGreg Pogue
Number of Employees 20
Contact Information

3333 Vaca Valley Pkwy Ste 1000

Vacaville, California 95688

lsbc.com

(707) 446-5501

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

News & Analysis

Filter by

large scale biology corp. - All News and Analysis

  • BIOREM announces $700,000 biotrickler order

    - 2009-06-02

    GUELPH, ON, June 2 /PRNewswire-FirstCall/ -- BIOREM Inc. (TSXV:BRM) announced today the receipt of a biotrickling filter order in Florida valued at $700,000. Biorem will supply three MytilusR biotrickling filtration systems to treat 24,000 cfm of polluted air streams with high hydrogen sulfide levels at a municipal...

  • Integrated Biomolecule acquires assets of PDI Analytical Laboratories

    - 2007-07-01

    Integrated Biomolecule Corp., IBC, Tucson, AZ, has acquired substantially all of the assets of PDI Analytical Laboratories, the analytical division of Large Scale Biology Corp. Included in the purchase are two tandem mass spectrometers (LCQ and Micro Q-TOF), a MALDI-TOF and a GC/MS used to detect, identify and quantify compounds...

  • MIT Enterprise Forum of Cambridge Features Case Presentation by Codon Devices, Synthetic Biology Pioneer

    - 2007-02-14

    Industry Experts to Discuss Marketing and Business Issues for Biotech Companies Targeting Major Pharmaceutical Firms CAMBRIDGE, Mass. -- The MIT Enterprise Forum of Cambridge What: The MIT Enterprise Forum of Cambridge will host a casepresentation by John Danner, president and CEO of Codon Devices, aprivately held biotechnology company...

  • XRIT, AURC, HLEG, LNVGY, LSBC, ONEI Have Also Been Removed From Naked Short List Today.

    - 2006-07-31

    M2 PRESSWIRE-31 July 2006-BUYINS.NET: XRIT, AURC, HLEG, LNVGY, LSBC, ONEI Have Also Been Removed From Naked Short List TodayC1994-2006 M2 COMMUNICATIONS LTD RDATE:31072006 www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short...

  • ATLO, CAB, IFN, RZ, UBFO, LSBC Have Been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days.

    - 2006-07-28

    M2 PRESSWIRE-28 July 2006-BUYINS.NET: ATLO, CAB, IFN, RZ, UBFO, LSBC Have Been On BUYINS.NET Naked Short List For 13 Consecutive Trading DaysC1994-2006 M2 COMMUNICATIONS LTD RDATE:28072006 BUYINS.NET, www.buyins.net, announced today that these select companies have been on the NASDAQ, AMEX and...

Decision Makers

Name (plus bio) Position
Greg Pogue Vice President and Executive Program Manager
Charles Crocker Director
Michael D. Centron Treasurer

Gregory Pogue serves as Vice President of Business Development for Emergent Technologies,Inc., and currently serves on the management teams for ETI portfolio companies Pure Vaccine Solutions and Pure Protein as President and Executive Vice President, respectively. As Vice President of Business Development at Emergent Technologies, Dr. Pogue is responsible for evaluating the commercial potential of new technologies, determining both technical and market trajectories, and building partnerships to effectively commercialize products. Dr. Pogue brings over twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. Dr. Pogue most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises. Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the US FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Before joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities. He holds a B.S. from Midwestern State University and a Ph.D. from Texas A&M University. Pogue has published numerous original scientific articles and reviews, is an inventor on multiple U.S. patents, and is a frequent invited speaker at national and international scientific meetings.

Organization Position Status
Pure Protein, Inc. President, Pure Vaccine Solutions, Executive Vice President Current
Large Scale Biology Corporation Vice President and Executive Program Manager Current
Emergent Technologies, Inc. Vice President of Business Development Current
The University of Texas at Austin Licensing Associate Former
Lsbc Ltd Former
Texas A&M University Ph.D. Former
Midwestern State University B.S. Former
Organization Position Status
Genelux Corporation Chairman and CEO, Crocker Capital, California Current
Crocker Capital, Inc. CEO Current
Genelux Corporation Business Advisor Current
S.O.S. Newall Limited Current
Crocker Capital, Inc. Chairman of the Board Current
Pope & Talbot, Inc. Chairman of Board Current
The Mary A. Crocker Trust Board of Directors Current
Storm Products Company Corp Board of Directors Current
Vicus Therapeutics, LLC Director Current
Mercator Medsystems, Inc Board of Directors Current
Large Scale Biology Corporation Director Current
Superconductor Technologies, Inc. Director Current
Teledyne Technologies Incorporated Director Current
Fiduciary Trust Company International Director Current
Coopervision, Inc. Director Current
The Mary A. Crocker Trust Trustee Current
Teledyne Technologies Incorporated Member of the Personnel & Compensation Committee Current
Bei Medical Systems Co., Inc. CEO Former
BEI Technologies, Inc. CEO Former
Bei Medical Systems Co., Inc. Founder Former
Schneider Electric Founder Former
Crocker Capital, Inc. Principal Current
Children's Hospital Chairman of the Board Former
BEI Technologies, Inc. Chairman of the Board Former
Pope & Talbot, Inc. Director Former
University of California, Berkeley M.B.A Former
Stanford University B.S. Degree Former

Michael D. Centron, Vice President and Treasurer, joined the Company in 1988 and has served as Treasurer since 1991. Prior to joining LSBC, Mr. Centron was Audit Supervisor for Varian Associates from 1985-1988, and also worked for Arthur Young and Co. (currently Ernst & Young). Mr. Centron is a certified public accountant and received his M.B.A. degree from the University of California, Berkeley.

Organization Position Status
Large Scale Biology Corporation Treasurer Current
Varian Semiconductor Equipment Associates, Inc. Audit Supervisor Former
Arthur Young, Inc. Former
University of California, Berkeley M.B.A. Degree Former
advertisement
Glass Door

Pharma Industry Companies

Company Employer Rating
Pfizer 3.0
IndustryTop Rated

Brought to you by CBS MoneyWatch.com